Grape King Bio (TPE:1707) Total Equity: NT$11,828 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:1707 Grape King Bio Ltd TPE:1707
79 GF Score
Price NT$90.10
GF Value NT$138.98
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Grape King Bio Total Equity?

Grape King Bio TPE:1707 -0.44% 79 Total Equity is NT$11,828 Mil as of Mar. 2026. GuruFocus rates TPE:1707 with a GF Score™ of 79/100 and a GF Value™ of NT$138.98 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Grape King Bio's total equity for the quarter that ended in Mar. 2026 was NT$11,828 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Grape King Bio Total Equity Historical Data

* Premium members only.

The historical data trend for Grape King Bio's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grape King Bio Total Equity Chart

Grape King Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10,429.42 11,141.07 11,629.94 11,790.70 12,066.39

Grape King Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11,527.62 11,122.52 11,638.09 12,066.39 11,827.81
TPE:1707
79GF Score
Grape King Bio Ltd TPE:1707
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Grape King Bio Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Grape King Bio's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=15738.289-3671.904
=12,066

Grape King Bio's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=15460.969-3633.156
=11,828

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of NT$11,828 Mil mean?
Grape King Bio (TPE:1707) has a Total Equity of NT$11,828 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Grape King Bio and its competitors.
Is Grape King Bio's Total Equity too high?
Grape King Bio's current Total Equity is NT$11,828 Mil. Overall, Grape King Bio has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Grape King Bio's Total Equity compare to ZTS?
Grape King Bio's Total Equity of NT$11,828 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Grape King Bio and its competitors. Grape King Bio's current Total Equity is NT$11,828 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grape King Bio stock overvalued right now?
Based on GuruFocus' analysis, Grape King Bio (TPE:1707) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$138.98, compared to a current price of NT$90.10 — trading 35.2% below its estimated fair value. The current Total Equity is NT$11,828 Mil. Grape King Bio's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Grape King Bio (TPE:1707), the current Total Equity is NT$11,828 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Grape King Bio (TPE:1707) Overvalued in 2026?

Based on GuruFocus' analysis, Grape King Bio stock appears to be undervalued. The current stock price of NT$90.10 is trading 35.2% below its estimated GF Value™ of NT$138.98. GuruFocus considers Grape King Bio to be Significantly Undervalued.

Key valuation signals for TPE:1707:

  • Total Equity: NT$11,828 Mil
  • GF Value™: NT$138.98 vs. price of NT$90.10 (35.2% below fair value)
  • GF Score™: 79/100 with 4 warning signs

No single metric tells the full story. See the TPE:1707 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Grape King Bio Business Description

Address Jinling Road, No. 402, Section 2, Pingzhen District, Pingzhen District, Taoyuan, TWN, 324
Grape King Bio Ltd is a specialty and generic drug manufacturing company engaged in producing and selling pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food. The company has three segments: MLM (Multi-Level Marketing), which is a direct seller of Pro-partner Inc, including the company's development and manufacturing products for Pro-partner Inc, the Distributors segment includes the company's self-owned brand products, and ODM/OEM (Original Design Manufacturer/Original Equipment Manufacturer) includes ODM/OEM in Taiwan and Shanghai. The group operates in three principal geographical areas - Taiwan, China, and Others, and it derives a majority of its revenue from Taiwan.
79GF Score

Get the complete analysis for TPE:1707

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$90.10
Price
NT$138.98
GF Value